Meta-Analysis of the Relation of Baseline Right Ventricular Function to Response to Cardiac Resynchronization Therapy




Right ventricular (RV) dysfunction has been associated with adverse clinical outcomes in patients with heart failure (HF). Cardiac resynchronization therapy (CRT) improves left ventricular (LV) size and function in patients with markedly abnormal electrocardiogram QRS duration. However, relation of baseline RV function with response to CRT has not been well described. In this study, we aim to investigate the relation of baseline RV function with response to CRT as assessed by change in LV ejection fraction (EF). A systematic search of studies published from 1966 to May 31, 2015 was conducted using PubMed, CINAHL, Cochrane CENTRAL, and the Web of Science databases. Studies were included if they have reported (1) parameters of baseline RV function (tricuspid annular plane systolic excursion [TAPSE] or RVEF or RV basal strain or RV fractional area change [FAC]) and (2) LVEF before and after CRT. Random-effects metaregression was used to evaluate the effect of baseline RV function parameters and change in LVEF. Sixteen studies (n = 1,764) were selected for final analysis. Random-effects metaregression analysis showed no significant association between the magnitude of the difference in EF before and after CRT with baseline TAPSE (β = 0.005, p = 0.989); baseline RVEF (β = 0.270, p = 0.493); baseline RVFAC (β = −0.367, p = 0.06); baseline basal strain (β = −0.342, p = 0.462) after a mean follow-up period of 10.5 months. In conclusion, baseline RV function as assessed by TAPSE, FAC, basal strain, or RVEF does not determine response to CRT as assessed by change in LVEF.


Right ventricular (RV) function is an independent prognostic marker for patients with heart failure (HF) and also plays an important role in determining the response to medical therapy in patients with HF. Recently, it has been suggested that baseline echocardiographic parameters of RV function could be helpful in identifying patients who respond more favorably to cardiac resynchronization therapy (CRT). However, studies have reported conflicting results, and the relation of baseline RV function with response to CRT remains unclear. In this study, we performed a meta-analysis of published studies and investigated the relation of various baseline echocardiographic parameters of RV function with response to CRT, as assessed by change in left ventricular (LV) ejection fraction (EF).


Methods


A systematic review of the reports was performed according to the Preferred Reporting Items for Systematic reviews and Meta-Analyses statement. We systematically searched PubMed, CINAHL, Cochran CENTRAL, Embase, Scopus, and Web of Science databases for all studies that reported parameters of RV function at baseline and LVEF before and after CRT implantation. All relevant combinations of the following keywords related to CRT were included in the search: RV function, tricuspid annular plane systolic excursion (TAPSE), RV diameters, RV short-axis diameter, RV long-axis diameter, RV fractional area change (FAC), and LVEF. The search was conducted from the inception of each database to May 31, 2015. No language or age restrictions were applied. Pertinent trials were also searched in clinicaltrials.gov and in the proceedings of major international cardiology meetings (American College of Cardiology, American Heart Association, European Society of Cardiology, and Heart Rhythm Society). Studies were included if they met each of the following 3 criteria: (1) human studies with participants of any age requiring CRT for any indication; (2) reported at least one parameter of baseline RV function (TAPSE, and/or RVEF, and/or RV long-axis diameter, and/or RV basal strain, and/or RVFAC); and (3) reported LVEF before and after CRT. Two independent reviewers (AS and SG) screened the titles and abstracts for relevance. Discrepancies between reviewers were discussed until consensus was reached. The manuscripts of selected titles/abstracts were reviewed for inclusion, and the investigators were contacted if additional data were needed. Using the previously mentioned selection criteria, these 2 reviewers independently determined the studies to be included and excluded, and data from the relevant studies were extracted using predefined extraction forms. Any disagreements in data extraction were discussed until consensus was reached.


In this analysis, Review Manager, version 5.1 (The Nordic Cochrane Center, The Cochrane Collaboration, 2008, Copenhagen) was used. A random-effects model with inverse variance weighting was used to calculate pooled mean difference in LVEF and corresponding CI. Heterogeneity between studies was assessed using Cochrane’s Q test and I 2 statistic, which denotes the percentage of total variation across studies that is a result of heterogeneity rather than chance. Heterogeneity was considered significant if the p value was <0.05. Publication bias was assessed by Begg’s test and Egger’s regression test. The influence of individual studies was examined by removing each study at a time to assess the degree to which meta-analysis estimate depends on a particular study (exclusion sensitivity analysis). Open Meta-Analyst software was used to perform random-effects metaregression to evaluate the effect of baseline RV function parameters on change in LVEF.




Results


We identified 17 studies, which reported parameters of baseline RV function and LVEF ( Figure 1 ). One study was not included in the final analysis, as it did not provide data in terms of absolute number (and SD) for baseline RV function parameters and LVEF before and after CRT. Sixteen studies were selected for final analysis. Details of the studies and baseline characteristics are summarized in Tables 1 and 2 .




Figure 1


Preferred reporting items for systematic reviews and meta-analyses flow sheet.


Table 1

Baseline characteristics of studies included in analysis
























































































































































































































































































































































First Author (Year) N Follow
up
(months)
NYHA
III/IV
Mean
QRS
duration
(msec)
RV function parameters LVEF LVEF at
end of
follow
up
FAC TAPSE RVEF RVLA Basal
Strain
Abu Sham’a [2012] 35 26.5 59%/- 173 ± 33 + 22 ± 5% 24 ± 7%
Abu Sham’a [2012] 158 26.5 52%/- 161 ± 30 + 25 ± 7% 30 ± 9%
Bleeker [2005] 56 6 89%/11% 176 ± 30 + 19 ± 6% 26 ± 8%
Boriani [2005] 15 3 80%/13% 189 ± 26 + 21 ± 9% 29 ±13%
Burri [2010] 44 9 70%/30% 162 ± 25 + 24 ± 8% 29 ±12%
D’Andrea [2009] 29 6 82%/18% 149 ± 22 + + 30 ± 5% 38 ±4%
D’Andrea [2009] § 41 6 82%/19% 149 ± 22 + + 31 ± 3% 38 ± 5%
D’Andrea [2009] 21 6 82%/18% 149 ± 22 + + 31 ± 3% 33 ± 4%
D’Andrea [2009] 19 6 82%/19% 149 ± 22 + + 29 ± 5% 32 ± 4%
Donal [2008] 50 3 68%/32% 163 ± 28 + + 22 ± 6% 27 ± 9%
Eder [2007] ∗∗ 16 6 + 22 ± 2% 20 ± 1%
Eder [2007] †† 12 6 + 20 ± 2% 30 ± 3%
Esmaeilzadeh[2011] ‡‡ 16 0.25 143 ± 19 + + + 19 ± 5% 24 ±19%
Esmaeilzadeh[2011] §§ 20 0.25 144 ± 15 + + + 19 ± 6% 23 ±8%
Knappe [2013] 63 12 0 + 24 ± 5% 37 ± 5%
Kusiak [2012] 57 3 184 ± 28 + 22 ± 5% 26 ± 5%
Leong [2013] 738 6 68%/9% 155 ± 33 + + 26 ± 8% 32 ±10%
Praus [2012] ¶¶ 38 15 193 ± 28 + 22 ± 5% 33 ±12%
Praus [2012] ‖‖ 19 15 195 ± 42 + 22 ± 7% 25 ±8%
Sade [2013] ∗∗∗ 31 32 142 ± 21 + + 21 ± 5% 25 ± 8%
Sade [2013] ††† 74 32 148 ± 22 + 24 ± 6% 35 ±11%
Scuteri [2009] 44 6 157 ± 25 + + 23 ± 5% 31 ±9%
Szulik [2011] 90 18 64%/36% 176 ± 29 + + 25 ± 8% 31 ±11%
Vitarelli [2011] ‡‡‡ 50 6 189 ± 24 + + + 19 ± 11% 32 ±15%
Vitarelli [2011] §§§ 31 6 171 ± 22 + + + 22 ± 8% 25 ±7%

– = no information available.

DCM = dilated cardiomyopathy; RVMD = right ventricular mechanical dyssynchrony; RVLA = right ventricle long-axis.

Moderate-to-severe TR.


No or mild TR.


Responder ischemic DCM.


§ Responder idiopathic DCM.


Nonresponder ischemic DCM.


Nonresponder idiopathic DCM.


∗∗ With increase in LVEF.


†† Without increase in LVEF.


‡‡ Patient with RVMD.


§§ Patient without RVMD.


¶¶ Responders.


‖‖ Nonresponders.


∗∗∗ Patient with events.


††† Patient without events.


‡‡‡ Responders.


§§§ Nonresponders.



Table 2

Baseline patient characteristics in the studies included in the analysis






















































































































































































































































































































































First Author (Year) Mean
age (yr.)
Male IC/NIC
Heart
Failure
LBBB/
RBBB
DM HTN HLD Smoker Beta-
blocker
ACE Spironolact
one/Loop
Diuretic
Abu Sham’a [2012] 69 ± 12 83% 71%/29% 43%/ 14%
Abu Sham’a [2012] 69 ± 10 87% 70%/30% 52%/ 13%
Bleeker [2005] 64 ± 11 79% 52%/48% 50% 52% – /82%
Boriani [2005] 62 ± 5 80% 47%/53%
Burri [2010] 72 ± 9 80% 57%/43% 73%/ 9% 12% 82% 95% – /80%
D’Andrea [2009] 57 ± 11 52% 100%/0 46% 35% 58% 44% 86% 95% 53%/95%
D’Andrea [2009] § 55+/-8 55% 0/100% 32% 33% 53% 35% 82% 94% 58%/96%
D’Andrea [2009] 57+/-11 52% 100%/0 46% 35% 58% 44% 86% 95% 53%/95%
D’Andrea [2009] 55 ± 8 55% 0/100% 32% 33% 53% 35% 82% 94% 58%/96%
Donal [2008] 67 ± 10 75% 45%/55%
Eder [2007] ∗∗ 67% 20%/80%
Eder [2007] †† 77% 23%/77%
Esmaeilzadeh [2011] ‡‡ 62 ± 10 58% 48%/56% 53%/ 6%
Esmaeilzadeh [2011] §§ 57 ± 13 58% 50%/50% 53%/ 7%
Knappe [2013] 64 ± 12 81% 51%/ – 78%/ – 84% 83% 43%/84%
Kusiak [2012] 66 ± 9 95% 72%/ – 40% 63% 77% 23% 96% 86% – /88%
Leong [2013] 67 78% 60%/ – 68%/ – 21% 71% 89% 47%/83%
Praus [2012] ¶¶ 67 ± 9 47%/47%
Praus [2012] ‖‖ 67 ± 9 74%/21%
Sade [2013] ∗∗∗ 60 ± 11 82% 71%/ – 68%/ 13% 83% 63% 83%/87%
Sade [2013] ††† 63 ± 11 81% 53%/ – 72%/ 5% 92% 92% 71%/84%
Scuteri [2009] 59 ± 10 81% 31%/ – 83% 95% 70%/100%
Szulik [2011] 57 ± 9 62% 41%/59% 88%/ – 22% 52% 100% 88% 84%/89%
Vitarelli [2011] ‡‡‡ 65 ± 13 64% 58%/42% 70% 93%
Vitarelli [2011] §§§ 63 ± 16 68% 68%/32% 84% 86%

– = no information available.

ACE = angiotensin-converting enzyme inhibitors; DCM = dilated cardiomyopathy; DM = diabetes mellitus; HLD = hyperlipidemia; HTN = hypertension; IC = ischemic cardiomyopathy; LBBB = left bundle branch block; NIC = nonischemic cardiomyopathy; RBBB = right bundle branch block ; RVMD = right ventricular mechanical dyssynchrony.

Moderate-to-severe TR.


No or mild TR.


Responder ischemic DCM.


§ Responder idiopathic DCM.


Nonresponder ischemic DCM.


Nonresponder idiopathic DCM.


∗∗ With increase in LVEF.


†† Without increase in LVEF.


‡‡ Patient with RVMD.


§§ Patient without RVMD.


¶¶ Responders.


‖‖ Nonresponders.


∗∗∗ Patient with events.


††† Patient without events.


‡‡‡ Responders.


§§§ Nonresponders.

Only gold members can continue reading. Log In or Register to continue

Stay updated, free articles. Join our Telegram channel

Nov 27, 2016 | Posted by in CARDIOLOGY | Comments Off on Meta-Analysis of the Relation of Baseline Right Ventricular Function to Response to Cardiac Resynchronization Therapy

Full access? Get Clinical Tree

Get Clinical Tree app for offline access